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Abstract
The aim of this paper is to discuss the use of Bayesian methods in cost-effectiveness analysis (CEA)
and the common ground between Bayesian and traditional frequentist approaches. A further aim is to
explore the use of the net benefit statistic and its advantages over the incremental cost-effectiveness
ratio (ICER) statistic. In particular, the use of cost-effectiveness acceptability curves is examined as a
device for presenting the implications of uncertainty in a CEA to decision makers. Although it is argued
that the interpretation of such curves as the probability that an intervention is cost-effective given the
data requires a Bayesian approach, this should generate no misgivings for the frequentist. Furthermore,
cost-effectiveness acceptability curves estimated using the net benefit statistic are exactly equivalent to
those estimated from an appropriate analysis of ICERs on the cost-effectiveness plane. The principles
examined in this paper are illustrated by application to the cost-effectiveness of blood pressure control
in the U.K. Prospective Diabetes Study (UKPDS 40). Due to a lack of good-quality prior information
on the cost and effectiveness of blood pressure control in diabetes, a Bayesian analysis assuming an
uninformative prior is argued to be most appropriate. This generates exactly the same cost-effectiveness
results as a standard frequentist analysis.
Economic evaluation of healthcare interventions is fundamentally concerned with decision
making. In the context of a budget-constrained system of health care, the effectiveness of
a healthcare intervention is a necessary but not sufficient condition for provision of that
intervention. The costs of health care must also be considered in order to achieve maximum
health gain from limited resources. Where a healthcare intervention is both more costly and
more effective, the ratio of the additional cost to additional effect (the incremental cost-
effectiveness ratio or ICER) is calculated in order to summarize the cost-effectiveness of
the intervention. If this ICER is less than some maximum willingness to pay for additional
health gain (or ceiling cost-effectiveness ratio, Rc), then the intervention is said to represent
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good value for money. If, however, the ICER is greater than Rc, the intervention is not
cost-effective and resources should be prioritized to other more worthwhile interventions.
Of course, estimates of the cost-effectiveness of healthcare interventions are subject
to uncertainty, which should be taken into account during the decision-making process.
With the growth of economic evaluation conducted alongside clinical trials, analysts are
increasingly in a position to handle statistically the uncertainty due to sampling variation.
This has engendered a growing interest in the use of statistical methods for cost-effectiveness
analysis. A recent area of interest has been the calculation of confidence intervals for cost-
effectiveness ratios, and the presentation of uncertainty in the results of cost-effectiveness
analysis (CEA) more generally (2;4;6;17;19;21;26;27;29).
The aim of this paper is to explore how Bayesian methods might be used to overcome
some of the problems encountered in cost-effectiveness studies when adopting a strictly
frequentist approach to handling uncertainty. It is sometimes thought that Bayesians and
frequentists inhabit different scientific paradigms that exclude any middle ground. How-
ever, there is an increasing acceptance of the fact that it is possible to exploit the natural
interpretation associated with a Bayesian approach to statistical analysis while retaining the
robustness of the frequentist approach (5;13;14).
Bayesian methods might usefully be classified into three main types, dependent on
the approach to prior information. Empirical Bayes describes the approach of estimating
prior distributions on the basis of statistical information available from the study sample.
A second Bayesian approach would be to assume an uninformative or reference prior
that purports to contain no information concerning the parameter of interest. The third
approach could be described as subjective Bayes, where prior information is elicited (in
a coherent fashion) from experts on the basis of their personal beliefs. The purpose of
such a classification is to emphasize that only the third type of approach is synonymous
with the subjective approach commonly considered (by frequentists) as introducing a lack of
robustness to statistical analysis. Hence, in this paper, the emphasis is on the overlap between
the frequentist approach and Bayes methods employing empirical or uninformative priors,
rather than on the subjective Bayes methods.
In addition to discussing the common ground between Bayesian and frequentist ap-
proaches to CEA, a further aim of the paper is to explore the use of the newly developed net
benefit statistic (26;27) and its advantages over the traditional ICER. The next section intro-
duces the standard frequentist approach to handling uncertainty in economic evaluation and
outlines the problems that can arise. The representation of uncertainty as a cost-effectiveness
acceptability curve is argued to provide the sort of information most useful for decision mak-
ers compared to standard confidence intervals. However, the interpretation of such curves
is most natural using a Bayesian approach. The third section therefore considers a Bayesian
approach to CEA. The net benefit statistic is employed in preference to the ICER due to its
desirable statistical properties. However, the overall equivalence of the net benefit and the
ICER is demonstrated by the equivalence of cost-effectiveness acceptability curves based
on the two approaches. The final section offers a discussion of the issues raised in this paper.
Initially, illustrative data are employed to elucidate the methods, and this is then followed by
a practical application of the Bayesian approach to the cost-effectiveness of tight blood pres-
sure control in hypertensive type 2 diabetic patients in the U.K. Prospective Diabetes Study
(UKPDS 40) (22). Since the focus of the paper is on the intuitive appeal of the Bayesian
approach rather than the technical aspects, statistical formulae are kept to a minimum.
HANDLING UNCERTAINTY IN COST-EFFECTIVENESS ANALYSIS
In an economic evaluation undertaken alongside a clinical trial, on the basis of data collected
from two groups of patients receiving alternative therapies, the ICER can be estimated by
Table 1. Results from a (Hypothetical) Randomized Controlled Trial of a New Therapy (Treat-
ment Group) Compared to an Existing Therapy (Control Group)
Mean SE Lower 95% Upper 95% Corr
Control group
Effect 8.89 0.26 8.39 9.39
Cost £25,080 £1,058 £23,006 £27,155 0.12
Treatment group
Effect 9.62 0.23 9.18 10.07
Cost £28,645 £1,421 £25,859 £31,430 ¡0.03
Difference
Effect 0.74 0.34 0.07 1.41
Cost £3,564 £1,772 £91 £7,037 0.03
ICER £4,836
Net Benefit £3,806 £3,803 ¡£3,648 £11,260
(Rc D £10,000)
ˆR D
¯CT ¡ ¯CC
¯E T ¡ ¯EC D
1 ¯C
1 ¯E
(1)
where ¯CT and ¯CC are the mean costs in the treatment and control arms of the trial, respec-
tively, and ¯E T and ¯EC are the mean effects.1 A traditional approach for handling uncertainty
due to sampling variation would be to estimate the confidence interval for the ICER and
compare the interval to the ceiling cost-effectiveness ratio, Rc. If the estimated interval is
found to be above Rc then the intervention is significantly cost-ineffective, with the im-
plication that the intervention should not be funded. If the estimated interval is found to
be below Rc, then the intervention is cost-effective with the implication that the treatment
should be funded.
Although this traditional approach does not appear contentious, it does present a number
of problems that are illustrated by means of an example. Consider a trial-based economic
analysis that generated the data shown in Table 1. Note from the table that the new therapy
has been shown to generate significant health outcome effects over the existing (control)
therapy. In practice, this is likely to mean that there will be pressure to implement this
intervention for the relevant patient group. However, the results also show the intervention
to be significantly more costly than the existing treatment for these patients. Consideration
should be given therefore to the ICER, which from Table 1 is estimated to be £4,836 per
unit of health gain. Suppose we know that the appropriate ceiling ratio for this decision is
£10,000 per unit effect, then the intervention looks as if it may offer good value for money.
If the confidence interval for the ICER excludes this value, then the intervention should be
implemented.
Ratio statistics pose particular problems for standard methods of calculating confidence
intervals when there is a non-negligible probability that the denominator of the ratio can
take a very small value. Applying the nonparametric bootstrap method (4;6;17) allows the
uncertainty in cost-effectiveness to be visualized and emphasizes some of the problems for
handling uncertainty in cost-effectiveness analysis. Figure 1 shows the bootstrap estimate
of the sampling distribution of the ICER for the data underlying the summary statistics
presented in Table 1, based on 1,000 bootstrap replications of the data in the treatment and
control groups. It is immediately apparent that the sampling distribution of the ICER in this
case does not follow a well-behaved distributional form. (Indeed, the histogram of Figure 1
Figure 1. Bootstrap estimate of the sampling distribution of the ICER for the data presented
in Table 1. (Note that the highest and lowest values are shown as a single bar in order to
present the histogram more clearly.)
Figure 2. Bootstrap replications of cost and effect differences on the cost-effectiveness
plane.
is truncated in order to present the distribution more clearly.) The most straightforward
method of obtaining a bootstrap 95% confidence interval is to select the 2.5th and 97.5th
percentile points of the vector of bootstrap replicates of the ICER—equivalent to cutting
2.5% from the tails of the estimated distribution shown in Figure 1. The resulting interval
on the basis of the bootstrap replicates from Figure 1 is ¡£772 to £24,646.
Note, however, that this interval is seriously misleading. Consider Figure 2, which
shows the same bootstrap replicates of the cost and effect differences plotted on the cost-
effectiveness (CE) plane. It is immediately apparent that although the majority of bootstrap
cost/effect pairs are falling in the northeast quadrant of the plane where the ICER is positive,
an important minority of cost/effect pairs fall in the southeast and northwest quadrants of the
plane where the ICER is negative. In the rank ordering process underlying the histogram of
Figure 1 and the percentile-based confidence interval, negative ratios are grouped together.
However, from a decision-making perspective negative ratios from different quadrants of
the CE plane are fundamentally different—a negative ratio due to a negative cost difference
implies that the new treatment is both cheaper and more effective than that currently pro-
vided, while a negative ratio due to a negative effect difference implies the exact opposite.
A practical solution to this problem would be to simply rank the negative ratios due to
negative effects above the highest positive ICER replicate and then estimate the percentile
confidence limits.2 While valid from a decision-making perspective, this approach is rather
suspect statistically since the problem identified above is a problem not of the statistical
method for calculating confidence limits (which is valid) but a problem of interpreting a
one-dimensional ratio, when the decision-making space is in fact two-dimensional (2).
Recently, a net benefit approach has been suggested that provides a solution to the
problem, providing that the ceiling ratio appropriate for decision making, Rc, is known
(26;27). This approach was also employed in an earlier paper by Claxton and Posnett (7)
that adopted a Bayesian approach to optimal trial design. The approach involves using the
value of Rc to rescale either the effect difference or the cost difference in order to provide a
net benefit statistic on the cost (7;27) or the effect scale (26). This is the same formulation
adopted by Phelps and Mushlin (20) to argue for the (near) equivalence of cost-benefit and
cost-effectiveness analyses, although they did not address the specific issue of uncertainty.
Since the net benefit statistics are exactly equivalent, the choice of scale is a matter of
preference. For this paper, the net benefit on the cost scale3 is used and defined as:
N B D Rc ¢1 ¯E ¡1 ¯C : (2)
Note that no problems of interpretation for the net benefit statistic arise: negative effect
differences with positive cost differences give a negative net benefit, while positive effect
differences and negative cost differences give a positive net benefit. Furthermore, in contrast
to the ICER, which does not have a mathematically tractable variance, the variance for net
benefit is simply defined in the standard way as:
var(N B) D R2c ¢ var(1 ¯E)C var(1 ¯C)¡ 2 ¢ Rc ¢ cov(1 ¯E;1 ¯C):
Therefore, the standard statistical approach would be to estimate the confidence interval for
net benefit and to see whether that interval excludes zero. In terms of Figure 2, employing
RcD £10,000 will lead to positive net-benefit for bootstrap replications to the right of the
line representing the decision rule and negative net-benefit to the left. A further advantage
of the net benefit statistic is its well-behaved statistical properties. Figure 3 shows the
histogram of the bootstrap estimate of the sampling distribution of the net benefit statistic
from Equation 2 as compared with the bootstrap estimate of the sampling distribution for
the ICER in Figure 1 (note that the same bootstrap replications are used in both figures).
Despite the desirable properties of the net benefit statistic, two problems remain. First,
what are the implications for decision making when the net benefit statistic is nonsignificant?
For example, Table 1 gives the bootstrap estimate of the 95% confidence interval for the
net benefit as¡£3,648 to £11,260, indicating that the intervention is not significantly cost-
effective at the 5% level. Secondly, the net benefit statistics rely on a predefined value for
Rc, whereas in fact the value of Rc is unknown.
Both these problems can be addressed simultaneously by plotting the cost-effectiveness
acceptability curve (28). In terms of net benefit, the curve can be estimated by plotting the
Figure 3. Bootstrap estimate of the sampling distribution of the net benefit statistic. (Note
that a normal distribution with the same mean and variance as the bootstrapped net benefit
data has been overlaid.)
(one-sided) confidence level at which the net benefit becomes significant as a function of Rc.
Although acceptability curves do not solve the problem of the unknown Rc, by conditioning
on its unknown value acceptability curves do summarize uncertainty in a way that is directly
relevant to the study question of whether the intervention under evaluation is cost-effective.
The acceptability curve was initially described in relation to cost-effectiveness ratios
and the cost-effectiveness plane (28), and can be equivalently thought of as considering
the proportion of bootstrap replications falling to the right side of the line representing Rc
in Figure 2 as the line is rotated counterclockwise from the horizontal (RcD 0) through to
the vertical (RcD1). Note that since both this approach and the net benefit approach will
identify the same bootstrap replications as cost-effective given the value of Rc, the resulting
(nonparametric) acceptability curves are (exactly) eqivalent. The cost-effectiveness accept-
ability curve for the data from Table 1 is presented in Figure 4. The curve cuts the vertical
axis at 0.022, which corresponds to the (one-sided) p value for cost difference. The point
estimate of the ICER (£4,836) corresponds to the 0.50 acceptability point4 and the curve is
tending to the value 0.969, which corresponds to one minus the (one-sided) p value for the
effect difference. If Rc for a particular decision maker were £10,000, then Figure 4 can be
used to determine that such a result would only be significant at the 20% level.
A frequentist interpretation of cost-effectiveness acceptability curves is possible by
considering that, conditional on the value of Rc, the acceptability curve indicates the (one-
sided) p values on the net benefit statistic as described above. However, the natural way to
interpret these curves (as illustrated by the labeling of the vertical axis in Figure 4) is as the
probability that the intervention is cost-effective, hence providing a direct answer to the study
question. Indeed, this is the way cost-effectiveness acceptability curves have been presented
in the literature to date (2;22;28), indicating that in the context of (typically) frequentist
trials, p values are being interpreted as probabilities. This may reflect that researchers want
to be able to make probability statements about the null hypothesis being false (1). Such
probability statements are only possible using a Bayesian view of the probability of the
hypothesis given the data.
Figure 4. Cost-effectiveness acceptability curve for the data from Table 1.
BAYESIAN METHODS FOR COST-EFFECTIVENESS ANALYSIS
Under a Bayesian interpretation, parameters of interest are ascribed a distribution reflecting
our uncertainty concerning the true value of the parameter. Fundamentally, the Bayesian
approach includes a learning process whereby beliefs concerning the distributions of param-
eters (prior distributions) are updated (to posterior distributions), as information becomes
available, through the use of Bayes’ theorem. Historically, advocates of the Bayesian ap-
proach were seen to inhabit a different scientific paradigm than the traditional long-run
frequency based methods, such that frequentists considered Bayesian methods as subjective
and highly dependent on prior beliefs, while their own methods were considered objective
and robust. However, the adoption of such an extreme position would be to reject a set of
very powerful methods that may be of import, even for frequentists (5). The empirical Bayes
methods and Bayesian analysis based on uninformative prior distributions are not subjec-
tive and have much to offer the frequentist analyst. In this section the standard Bayesian
approach is set out in general terms and the updating procedure is shown for normally
distributed variables, and a Bayesian analysis of the U.K. PDS trial is illustrated.
Bayes Theorem and the Normal Distribution
Bayes theorem can be written as the relationship between the posterior distribution of µ
(the vector of parameters of interest) h(µ j x), the prior distribution function g(µ ), and the
observed data X with a density function f (x j µ ) such that:
h(µ j x) D f (x j µ )g(µ )Z
f (x j µ )g(µ ) dµ
It is this equation that gives rise to the common expression of the Bayesian posterior
distribution as proportional to the prior times the likelihood.
It is common for prior distributions to be specified in terms of a distribution that is conju-
gate to the distribution of the observed data for mathematical convenience. Conjugate priors
lead to posterior distribution from the same family of distributions (23), which make the cal-
culation of the posterior distribution more straightforward. Although the advent of powerful
desktop computers and appropriate software based on Markov chain Monte Carlo methods
(such as WinBUGS, developed by the MRC Biostatistics Unit at Cambridge University,
U.K., and available for download from their website: www.mrc-bsu.cam.ac.uk/bugs/) has
meant that this is no longer strictly necessary, there is added convenience when the calcu-
lations can be undertaken in closed analytical form. In particular, the normal distribution is
self-conjugate such that normal data and normal prior lead to a normal posterior distribution.
Suppose that a normal likelihood adequately describes the data likelihood function
such that X » N („; ¾ 2) and the prior distribution of µ can also be expressed in terms of
a normal distribution, such as N (¿; !2). Putting these distributions into the expression for
Bayes theorem given above yields the result that the posterior distribution for µ is given as:
h(µ j x) D N
ˆ
!2„C ¾ 2¿
!2 C ¾ 2 ;
$ 2¾ 2
!2 C ¾ 2
!
:
Defining W D!2=(!2C ¾ 2) simplifies the above expression to:
h(µ j x) D N (W„C (1¡W )¿;W¾ 2):
Thus, the mean and variance of the posterior distribution can be seen as a weighted average
of the means and variances of the prior and likelihood functions. If the variance of the prior
distribution is very large compared with that of the data likelihood, then the weight given
to the prior mean and variance will be very small. A noninformative prior is equivalent to a
very large variance for the prior. Since as !2!1, W! 1, it is clear that a noninformative
prior leads to a posterior distribution that is dominated by the data likelihood such that
h(µ j x)D N („; ¾ 2). Thus, in the case of normally distributed likelihood and priors, there
will be equivalence between the frequentist approach and the Bayesian posterior arising
from the use of a noninformative prior.
For CEA, the net benefit statistic will be much more convenient to handle in a Bayesian
analysis than would the ICER statistic, since it is clear from the example given above that the
net benefit statistic is well behaved (Figure 3), closely approximating a normal distribution,
when the ICER statistic has a highly erratic distribution caused by non-negligible probability
of the denominator of the ratio in the neighborhood of zero.
A Bayesian Approach to the Cost-effectiveness of Tight
Blood Pressure Control in Diabetic Patients
To illustrate a Bayesian approach to CEA, data from the recently completed UKPDS 40 are
employed. These data relate to a CEA designed to assess the efficiency of tight blood pres-
sure control compared with less tight control in hypertensive patients with type 2 diabetes
(22). Hypertension in subjects with type 2 diabetes is a risk factor for macrovascular com-
plications. Although improved blood pressure control has been shown to reduce myocardial
infarction and stroke in a diabetic subgroup of elderly patients with type 2 diabetes (24), no
information on younger patients or the effect on complications of diabetes was available.
The authors of the original CEA noted that although cost-effectiveness of antihypertensive
programs based on education and drugs has been reported for a number of populations:
: : :these analyses have mainly been based on models and lack information on effectiveness and use of
resources from long term trials, and none has considered hypertensive patients with type II diabetes.
(22, p. 720)
Table 2. Summary Statistics for the Cost-effectiveness of Tight Blood Pressure Control
Compared to Less Tight Control in the U.K. Prospective Diabetes Study
Mean SE Lower 95% Upper 95%
Control group
Effect 10.30 0.17 9.97 10.64
Cost £6,145 £434 £5,294 £6,996
Treatment group
Effect 10.63 0.12 10.41 10.96
Cost £6,381 £309 £5,775 £6,987
Difference
Effect 0.33 0.21 ¡0.08 0.73
Cost £236 £533 ¡£808 £1,280
ICER £720 N/A N/A N/A
Net benefit £3,041 £2,135 ¡£1,143 £7,226
(Rc D £10,000)
The authors then report the results of their study in the form of incremental costs,
incremental effects, and employing the cost-effectiveness acceptability curve approach.
These results, assuming standard practice costs and discount rates of 6% for both costs
and life-years, are reproduced in Table 2. Also included in Table 2 is an assessment of the
net benefit of tight blood pressure control assuming a ceiling ratio for decision making of
£10,000 per year of life gained. It is clear from Table 2 that although tight blood pressure
control looks both more effective (in terms of life-years gained) and more costly, neither
of these differences are statistically significant at conventional levels. Furthermore, the net
benefit statistic shows a positive net benefit at RC D £10,000 but is also nonsignificant. A
naı¨ve economic analysis might conclude that there was nothing to choose between these two
treatments; however, this would ignore the wealth of information built up in the UKPDS 40
over an 11-year median follow-up time that the effectiveness of treatment is approaching
the standard level of statistical significance. Indeed, the clinical endpoint of time to a
diabetes-related event was shown to have a statistically significant difference between the
two treatments. Instead the authors presented the results of their analysis in terms of a
cost-effectiveness acceptability curve showing, for example, that for RC D £10,000, there
is a 92% probability that the intervention is cost-effective.
Of course, such an interpretation is only possible using a Bayesian view of probability.
The quote from the original paper above indicates that the authors of the original study
had considered that there was little information on the cost-effectiveness of tight blood
pressure control for patients with diabetes prior to their reported results. However, a search
of a database of cost-effectiveness analyses reporting cost per QALY and cost per life-year
results (3) for economic analyses of hypertension control conducted alongside a clinical
trial identified an economic analysis of the Swedish Trial of Old Patients with Hypertension
(the STOP Hypertension study) (8;15). Clearly, the population studied (elderly Swedish
patients without diabetes) differed from that of hypertensive patients in the UKPDS 40,
but in the absence of other information, this trial might be seen as providing at least some
information of the likely costs and effects that might be observed in the UKPDS population.
Taking the average estimates of the life-years gained and costs reported in the economic
analysis of the STOP study suggests that an estimated 0.16 life-year might be gained
from treatment at an additional cost of approximately £1,400 (converted from Swedish
crowns and inflated to 1996 prices). Unfortunately, there was little information on sampling
variation given in the economic analysis of the STOP study, and standard errors on cost
Figure 5. Bayesian approach to cost-effectiveness analysis of tight blood pressure control
for hypertensive diabetic patients. Two posterior distributions for net benefit are employed
based on a prior distribution from previous studies (shown) and an uninformative prior.
and effect differences were not given. Therefore, the standard errors were set arbitrarily
to give a coefficient of variation on cost and effect equal to 2 in order to be conservative
and to reflect the fact that the different methods employed in the economic analysis, the
difference between the patient populations, and the difference between the two countries’
healthcare systems will all increase the level of uncertainty associated with these prior
estimates.
Using the net benefit approach (RcD £10,000), Figure 5 presents this prior infor-
mation and the posterior distribution arising from employing this information together
with the data from Table 2. The alternative would be to employ an uninformative prior
such that the posterior distribution produced is dominated by the observed data—either
because no prior information is available or because the analyst wishes to discard that
information. The posterior distribution based on the uninformative prior is also shown
in Figure 5—and exactly corresponds with the frequentist notion of likelihood for net
benefit for the reasons outlined above. It is clear that incorporating the prior informa-
tion reduces the variance of the posterior distribution, but that the point estimate of net
benefit is weighted most heavily toward the existing data. This is because the Bayesian ap-
proach weights the prior information in relation to its variance compared with the observed
data.
Having estimated the prior and posterior distributions for net benefit using Bayesian
methods, the probability of the intervention being cost-effective can then be plotted as a
function of Rc in order to generate cost-effectiveness acceptability curves. Figure 6 shows
the results; as argued above, it is these curves that give the information that is most relevant
to decision makers. Just as the Bayesian posterior distribution of net benefit corresponds
to the frequentist likelihood, so the cost-effectiveness acceptability curve plotted under the
assumption of a noninformative prior will correspond exactly to a cost-effectiveness accept-
ability curve calculated by frequentist methods (involving the less natural interpretation of
the curve based on p values).
Figure 6. Bayesian approach to cost-effectiveness analysis of tight blood pressure control
for hypertensive diabetic patients. Two posterior cost-effectiveness acceptability curves are
generated based on a prior distribution from previous studies (shown) and an uninformative
prior.
DISCUSSION
In undertaking an economic evaluation of a healthcare intervention, the study question is
likely to be: is the intervention cost-effective? Where the evaluation is carried out by means
of an experiment with patient-level data generated on costs and effects, it will be natural
to consider uncertainty due to sampling variation in a statistical manner. The Bayesian
approach offers an important and powerful set of methods to the economic analyst seeking
to advise policy decisions because it allows the study question to be addressed directly.
Furthermore, this paper has demonstrated how Bayesian methods can be used in a way
entirely consistent with the desire by frequentists for an objective approach to statistical
analysis through the use of empirical or noninformative priors. In particular, the Bayesian
approach allows a more natural way of interpreting cost-effectiveness acceptability curves.
Bayesian methods also provide a natural iterative approach to meta-analysis where the
evidence from new trials is simply added as it becomes available (10;11;14), compared
with conducting experiments in apparent isolation and then pooling the results, which
is the frequentist approach to meta-analysis. Some Bayesians would argue that such an
approach is not in fact Bayesian at all since no subjective beliefs are employed. For example,
Spiegelhalter and colleagues (25) argue that, while previous results should form the basis of
prior distributions, those results should not specify the distribution completely. Referencing
Kass and Greenhouse (16), they go on to argue that to do so would be to treat historical and
current data as exchangeable, which is in essence equivalent to simply pooling the results.
While a common perception of Bayesian methodology is that it is inherently subjec-
tive, some authors have gone to some lengths to emphasize the robustness and objectivity
of the application of Bayesian methods (5;14). Furthermore, most Bayesians would be un-
comfortable in a situation where the choice of different potential prior distributions has
important effects on the posterior distribution (i.e., where the data do not dominate the
prior), hence the emphasis in many texts on sensitivity analysis and Bayesian “robustness”
(5;12). Moreover, while subjective priors have a role in personal decision making, it is less
clear whether decision makers should be employing subjective beliefs in decisions taken on
behalf of society. The recent interest in medical practice having an evidence base could be
seen as a way of improving the objectivity of decision making and reducing the influence of
personal belief concerning the effectiveness of treatments. What is needed is a “policing”
of priors such that if a large number of clinicians disagree as to their prior beliefs con-
cerning the likely effectiveness of an intervention, then this relative uncertainty is included
in any Bayesian analysis through the use of a “societal” prior that reflects the underlying
uncertainty among experts. Such a composite prior would by definition be relatively nonin-
formative where experts were in disagreement, and therefore any analysis should be largely
dominated by the data. By representing diverse individual priors as a vague overall prior,
what is potentially a diverse set of posterior distributions from the application of subjec-
tive Bayes methods at a personal level becomes a single posterior that incorporates prior
uncertainty among experts at the level of society.
At present, and most likely in the immediate future, health economists conducting eco-
nomic analyses alongside clinical trials will have to work within the sample size constraints
imposed by clinical investigators. This is likely to generate the situation where important
economic differences cannot be detected at conventional levels of power and significance.
A number of commentators have suggested that it may be appropriate for economic ana-
lysts to work with error rates (in the frequentist sense) that are higher than those employed
in clinical evaluation (9;18). This suggestion indicates the desire of economic analysts to
consider the weight of evidence relating to the cost-effectiveness of the intervention under
evaluation rather than relying on showing significance at conventional levels. This is most
easily achieved through the use of cost-effectiveness acceptability curves that show the
weight of evidence for the intervention being cost-effective for all possible values of the
ceiling ratio, Rc.
In the original economic evaluation of hypertension control in the UKPDS 40 (22), the
authors presented their results in the form of a cost-effectiveness acceptability curve. This
paper has demonstrated how prior information on the costs and effects of this intervention
could have been incorporated into the analysis. However, this illustration of the Bayesian
approach was intended to be illustrative. Given the lack of prior information on the costs
and effects of hypertension control for patients with diabetes, the use of a noninformative
prior (consistent with the authors’ approach and equivalent to a frequentist analysis) was
entirely appropriate.
In this paper, the focus has been on estimating the posterior distribution of the parame-
ter of interest (net benefit) and using this to generate cost-effectiveness acceptability curves.
A full Bayesian analysis might specify a loss function for decision making in order to es-
timate the optimal decision strategy (i.e., that which minimizes the loss function). Claxton
and Posnett (7) have specified such a loss function in terms of Rc, which they have em-
ployed to determine the optimal size for clinical trials. However, uncertainty concerning the
appropriate value for Rc, and the possibility that such a value might vary between decision
makers and over time, may mean that the clear specification of the posterior distribution
that could then be used by decision makers in conjunction with their own loss function may
be more appropriate, although this is undoubtedly an area for further research.
The increasing interest in value for money in the area of health care has resulted
in many more clinical trials incorporating an economic analysis as part of their design.
As these trials come to be reported, many more analysts are going to face the sorts of
problems in representing uncertainty highlighted in this paper. Fortunately, past acrimony
between the Bayesian and frequentist schools appears to have been laid aside in favor of
a more harmonious coexistence. Two things are clear: a) Bayesian methods allow ana-
lysts to address the fundamental question of whether an intervention is cost-effective; and
b) the normative question of how to allocate scarce healthcare resources in a publicly funded
healthcare system requires an evidence base such that Bayesian posterior distributions are
dominated by the available data rather than by subjective belief.
NOTES
1 This formulation assumes that patients are homogeneous with respect to risk factors for treat-
ment effect across all patients on the absolute scale. This may be a very strong assumption in many
circumstances. A weaker assumption might be that treatment odds ratios are constant, but that absolute
risks can vary across patients. Average treatment effect on the absolute scale could then be modeled.
2 Such a solution would work in this case since there are no positive bootstrap replications in the
southwest quadrant of the plane. Note that positive replications in the southwest quadrant follow the
opposite ordering from those in the northeast quadrant since high values of the ICER when both costs
and effect differences are negative are relatively more favorable to the intervention under evaluation
than low ICERs.
3 The advantages of using the cost scale are that such a formulation corresponds with economists’
traditional notion of cost-benefit analysis (20) and that the point estimate of net benefit given in
equation 2 is clearly linear in the unknown Rc. However, it has been argued that the use of the health
scale to represent net health benefit would have the advantage of emphasizing the opportunity cost of
resource expenditure directly in terms of health benefits forgone (26).
4 This correspondence between the ICER and the 0.50 point occurs in this example because it
was shown that net benefit is normally (i.e., symmetrically) distributed. In general, this 0.50 point on
the acceptability curve will not correspond to the point estimate of the ICER if bootstrapping indicates
a skewed distribution for the net benefit.
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